HomeHealthAmarin to Present at H.C. Wainwright's 24th Annual Global Investment Conference

Amarin to Present at H.C. Wainwright’s 24th Annual Global Investment Conference

Published on

DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 30, 2022 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin’s president and chief executive officer, is scheduled to participate at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022.


H.C. Wainwright 24


th


Annual Global Investment Conference

(September 12-14

th

, 2022; New York, New York)

Date/Time:       September 12, 2022, 9:00 a.m. ET/ 1:00 p.m. GMT+1

Webcast:          https://journey.ct.events/view/d9528c72-e456-4ecb-937c-aeb7449d2c5d

The conference presentation will be webcast live and archived on the Company’s website in the Investor Relations section under Events and Presentations at

Events | Amarin Corporation plc

.


About Amarin

Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From our foundation in scientific research to our focus on clinical trials, and now our commercial expansion, we are evolving and growing rapidly. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and suppliers around the world. We are committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk.


Availability of Other Information About Amarin

Amarin communicates with its investors and the public using the company website (

www.amarincorp.com

) and the investor relations website (investor.amarincorp.com), including but not limited to investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.


Amarin Contact Information


Investor Inquiries:

Investor Relations

Amarin Corporation plc


[email protected]

(investor inquiries)

Media Inquiries:

Communications

Amarin Corporation plc


[email protected]

(media inquiries)

ti?nf=ODYzNjkwMiM1MTI1NzI4IzIwMjc3OTY= Amarin to Present at H.C. Wainwright's 24th Annual Global Investment Conference


Primary Logo

Featured image: Megapixl © Freebird7977

Disclaimer

Latest News

BD, CerTest Biotec Announce US Commercial Launch of Monkeypox Assay

BD, CerTest Biotec Announce US Commercial Launch of...

Creative Medical Technology Announces Peer Reviewed Publication of Positive Results for StemSpine® Study

Creative Medical Technology Announces Peer Reviewed Publication of...

Centene Subsidiary Selected to Continue Serving Nebraska’s Medicaid Managed Care Members

Centene Subsidiary Selected to Continue Serving Nebraska's Medicaid...

More like this

Optimi Health, ATMA Journey Centers To Proceed With Phase I Natural Psilocybin and MDMA Clinical Trial Application to Health Canada

Optimi (CSE:OPTI)(OTCQX:OPTHF)(FRA:8BN) aiming to become the first vertically integrated psychedelics firm to formulate and...

GSK and Spero Therapeutics Announce Exclusive License Agreement for Late-Stage Antibiotic Asset, Tebipenem HBr

The exclusive license allows GSK to commercialize tebipenem HBr in...

iBio Acquires RubrYc Therapeutics’ AI Drug Discovery Platform and Pipeline

– Positions Company for leadership in AI-powered drug discovery – ...

CVS Health reports progress against goal to reduce suicide attempts among Aetna members 20% by 2025

CVS Health reports progress against goal to reduce...